Fang J C, Kinlay S, Kundsin R, Ganz P
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Am J Cardiol. 1998 Dec 15;82(12):1479-83. doi: 10.1016/s0002-9149(98)00723-1.
We sought to explore the relation between Chlamydia pneumoniae, cytomegalovirus (CMV), and cardiac transplant-associated arteriosclerosis. Serologic evidence of past Chlamydia pneumoniae infection was investigated in 3 patient groups at the time of cardiac catheterization: cardiac transplant recipients (n=49), patients having coronary artery bypass grafting (CABG) (n=39), and a control group free of angiographic coronary artery disease (n=21). High Chlamydia pneumoniae immunoglobulin G titers (> or =1:160) were more frequently observed in cardiac transplant recipients (odds ratio[OR] 13.7; 95% confidence intervals [CI] 1.6 to 117.4, p <0.05) and CABG patients (OR 21.7; 95% CI 1.6 to 287.0, p <0.05) than in controls. However, high Chlamydia pneumoniae titers did not distinguish between cardiac transplant recipients with or without angiographic transplant-associated arteriosclerosis or CABG patients with or without bypass vein graft disease. Furthermore, there was no significant relation between elevated Chlamydia pneumoniae titers and the presence or progression of transplant-associated arteriosclerosis in the subgroup of patients who were also CMV positive. Yet, analysis of the same angiograms demonstrated an association between CMV infection and the recent progression of transplant-associated arteriosclerosis. Thus, patients with cardiac transplantation have evidence of past Chlamydia pneumoniae and CMV infection but Chlamydia pneumoniae does not appear to have an independent role or synergistic relation to CMV in the development of transplant-associated arteriosclerosis.
我们试图探究肺炎衣原体、巨细胞病毒(CMV)与心脏移植相关动脉硬化之间的关系。在进行心导管检查时,对3组患者调查了既往肺炎衣原体感染的血清学证据:心脏移植受者(n = 49)、接受冠状动脉搭桥术(CABG)的患者(n = 39)以及无血管造影冠状动脉疾病的对照组(n = 21)。与对照组相比,心脏移植受者(优势比[OR] 13.7;95%置信区间[CI] 1.6至117.4,p <0.05)和CABG患者(OR 21.7;95% CI 1.6至287.0,p <0.05)中更常观察到高肺炎衣原体免疫球蛋白G滴度(≥1:160)。然而,高肺炎衣原体滴度并不能区分有或无血管造影移植相关动脉硬化的心脏移植受者,也不能区分有或无搭桥静脉移植物疾病的CABG患者。此外,在同样为CMV阳性的患者亚组中,肺炎衣原体滴度升高与移植相关动脉硬化的存在或进展之间没有显著关系。然而,对相同血管造影的分析显示CMV感染与移植相关动脉硬化的近期进展之间存在关联。因此,心脏移植患者有既往肺炎衣原体和CMV感染的证据,但肺炎衣原体在移植相关动脉硬化的发生发展中似乎没有独立作用,也与CMV没有协同关系。